Nuveen Asset Management LLC Has $293.97 Million Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Nuveen Asset Management LLC trimmed its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 0.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 494,626 shares of the biotechnology company's stock after selling 2,800 shares during the quarter. Nuveen Asset Management LLC owned 0.65% of Axon Enterprise worth $293,966,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of AXON. New Wave Wealth Advisors LLC bought a new stake in shares of Axon Enterprise during the fourth quarter worth $40,000. Y.D. More Investments Ltd acquired a new position in Axon Enterprise in the 4th quarter worth $45,000. Stonebridge Financial Group LLC bought a new position in Axon Enterprise during the 4th quarter worth about $53,000. GPS Wealth Strategies Group LLC raised its stake in shares of Axon Enterprise by 74.1% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 40 shares during the period. Finally, Berbice Capital Management LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter valued at about $59,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Stock Performance

Shares of AXON stock traded up $4.79 during trading on Friday, reaching $733.18. 419,101 shares of the company's stock were exchanged, compared to its average volume of 759,084. Axon Enterprise, Inc. has a twelve month low of $273.52 and a twelve month high of $735.68. The firm's fifty day moving average price is $584.61 and its 200-day moving average price is $594.51. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $57.08 billion, a PE ratio of 189.45, a PEG ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The firm had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The company's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.15 earnings per share. As a group, sell-side analysts anticipate that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Insider Buying and Selling

In other news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the transaction, the chief executive officer now owns 3,063,982 shares in the company, valued at approximately $1,657,583,622.18. This trade represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeri Williams sold 307 shares of Axon Enterprise stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $552.72, for a total value of $169,685.04. Following the sale, the director now directly owns 1,627 shares of the company's stock, valued at approximately $899,275.44. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,764 shares of company stock valued at $14,856,635. Company insiders own 4.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on AXON shares. JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 4th. Northcoast Research downgraded Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. Craig Hallum downgraded shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. The Goldman Sachs Group boosted their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Barclays upped their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $652.73.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.